These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 1728981)

  • 21. Use of Tripterygium wilfordii Hook F for immune-mediated inflammatory diseases: progress and future prospects.
    Song CY; Xu YG; Lu YQ
    J Zhejiang Univ Sci B; 2020 Apr.; 21(4):280-290. PubMed ID: 32253838
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pyrimethamine treatment does not ameliorate lymphoproliferation or autoimmune disease in MRL/lpr-/- mice or in patients with autoimmune lymphoproliferative syndrome.
    Rao VK; Dowdell KC; Dale JK; Dugan F; Pesnicak L; Bi LL; Hoffmann V; Penzak S; Avila NA; Fleisher TA; Puck JM; Straus SE
    Am J Hematol; 2007 Dec; 82(12):1049-55. PubMed ID: 17674358
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nephritogenicity of the lprcg gene on the MRL background.
    Kimura M; Ogata Y; Shimada K; Wakabayashi T; Onoda H; Katagiri T; Matsuzawa A
    Immunology; 1992 Jul; 76(3):498-504. PubMed ID: 1526655
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Type I IFN protects against murine lupus.
    Hron JD; Peng SL
    J Immunol; 2004 Aug; 173(3):2134-42. PubMed ID: 15265950
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vivo treatment with a monoclonal antibody to interferon-gamma neither affects the survival nor the incidence of lupus-nephritis in the MRL/lpr-lpr mouse.
    Nicoletti F; Meroni P; Di Marco R; Barcellini W; Borghi MO; Gariglio M; Mattina A; Grasso S; Landolfo S
    Immunopharmacology; 1992; 24(1):11-6. PubMed ID: 1452442
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduction of lupus nephritis in MRL/lpr mice by a bacterial superantigen treatment.
    Kim C; Siminovitch KA; Ochi A
    J Exp Med; 1991 Dec; 174(6):1431-7. PubMed ID: 1744580
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Treatment of rheumatoid arthritis with tripterygium wilfordii hook. I. Effect on secretion of total IgM and IgM-RF by peripheral blood mononuclear cells (PBMC)].
    Tao XL
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1988 Oct; 10(5):361-4. PubMed ID: 2978257
    [No Abstract]   [Full Text] [Related]  

  • 28. Protection against autoimmune nephritis in MyD88-deficient MRL/lpr mice.
    Sadanaga A; Nakashima H; Akahoshi M; Masutani K; Miyake K; Igawa T; Sugiyama N; Niiro H; Harada M
    Arthritis Rheum; 2007 May; 56(5):1618-28. PubMed ID: 17469144
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Suppression of lupus nephritis and skin lesions in MRL/lpr mice by administration of the topoisomerase I inhibitor irinotecan.
    Keil A; Hall SR; Körner M; Herrmann M; Schmid RA; Frese S
    Arthritis Res Ther; 2016 Oct; 18(1):243. PubMed ID: 27770825
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effect of External Applying Compound Tripterygium wilfordii Hook F. on Joint Pain of Rheumatoid Arthritis Patients].
    Jiao J; Tang XP; Yuan J; Liu X; Liu H; Zhang CY; Wang LY; Jiang Q
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2016 Jan; 36(1):29-34. PubMed ID: 26955673
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of circulating miR-146a in patients with rheumatoid arthritis treated by Tripterygium wilfordii Hook F.
    Chen ZZ; Zhang XD; Chen Y; Wu YB
    Medicine (Baltimore); 2017 May; 96(20):e6775. PubMed ID: 28514293
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tripterygium wilfordii Hook F as Maintenance Treatment for Crohn's Disease.
    Sun J; Shen X; Dong J; Wang H; Zuo L; Zhao J; Zhu W; Li Y; Gong J; Li J
    Am J Med Sci; 2015 Nov; 350(5):345-51. PubMed ID: 26473333
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    Wang Y; Tian Z; Huang S; Dang N
    Drug Des Devel Ther; 2023; 17():3767-3781. PubMed ID: 38144417
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The proliferative in vivo activities of lpr double-negative T cells and the primary role of p59fyn in their activation and expansion.
    Balomenos D; Rumold R; Theofilopoulos AN
    J Immunol; 1997 Sep; 159(5):2265-73. PubMed ID: 9278315
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Terminal deoxynucleotidyl transferase deficiency decreases autoimmune disease in MRL-Fas(lpr) mice.
    Feeney AJ; Lawson BR; Kono DH; Theofilopoulos AN
    J Immunol; 2001 Sep; 167(6):3486-93. PubMed ID: 11544342
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Chinese herb Tripterygium wilfordii Hook F in the treatment of rheumatoid arthritis: mechanism, efficacy, and safety.
    Bao J; Dai SM
    Rheumatol Int; 2011 Sep; 31(9):1123-9. PubMed ID: 21365177
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic potential of demethylzeylasteral, a triterpenoid of the genus Tripterygium wilfordii.
    Sun X; Shen B; Yu H; Wu W; Sheng R; Fang Y; Guo R
    Fitoterapia; 2022 Nov; 163():105333. PubMed ID: 36244595
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CD47 deficiency ameliorates autoimmune nephritis in Fas(lpr) mice by suppressing IgG autoantibody production.
    Shi L; Bian Z; Chen CX; Guo YN; Lv Z; Zeng C; Liu Z; Zen K; Liu Y
    J Pathol; 2015 Nov; 237(3):285-95. PubMed ID: 26095930
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low-dose of multi-glycoside of Tripterygium wilfordii Hook. f., a natural regulator of TGF-β1/Smad signaling activity improves adriamycin-induced glomerulosclerosis in vivo.
    Wan YG; Che XY; Sun W; Huang YR; Meng XJ; Chen HL; Shi XM; Tu Y; Wu W; Liu YL
    J Ethnopharmacol; 2014 Feb; 151(3):1079-1089. PubMed ID: 24362077
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of immunological effects of cholera toxin on autoimmune MRL/lpr and BXSB mice.
    Zhou NN; Nakai S; Oka M; Nagasawa H; Himeno K
    Microbiol Immunol; 1992; 36(7):745-56. PubMed ID: 1406377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.